BEUDAMED
    FDA Adverse Event Injury Summary report: N

    COREVALVE TRANSCATHETER AORTIC VALVE

    MDR report key: 15513876 · Received September 30, 2022

    Report

    Report Number
    2025587-2022-02687
    Event Type
    Injury
    Date Received
    September 30, 2022
    Date of Event
    August 8, 2022
    Report Date
    September 29, 2022
    Manufacturer
    MEDTRONIC HEART VALVES DIVISION
    Product Code
    NPT
    PMA / PMN Number
    P130021
    Adverse Event
    Yes
    Product Problem
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    IS
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    CITATION: LANDES U.; ET AL. OUTCOMES OF REDO TRANSCATHETER AORTIC VALVE REPLACEMENT ACCORDING TO THE INITIAL AND SUBSEQUENT VALVE TYPE. J AM COLL CARDIOL INTV. 2022 AUG 8; 15(15):1543¿1554. DOI.ORG/10.1016/J.JCIN.2022.05.016. EARLIEST DATE OF PUBLICATION USED FOR DATE OF EVENT. MEDTRONIC PRODUCTS REFERENCED: COREVALVE (PMA# P130021, PRODUCT CODE: NPT). EARLIEST APPROVED PRODUCT USED FOR PRODUCT CODE AND PMA#. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. MEDTRONIC IS SUBMITTING THIS REPORT TO COMPLY WITH FDA REPORTING REGULATIONS UNDER 21 CFR PARTS 4 AND 803. THIS REPORT IS BASED UPON INFORMATION OBTAINED BY MEDTRONIC, WHICH THE COMPANY MAY NOT HAVE BEEN ABLE TO FULLY INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY THE FDA. MEDTRONIC HAS MADE REASONABLE EFFORTS TO OBTAIN MORE COMPLETE INFORMATION AND HAS PROVIDED AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. IN PARTICULAR, THIS REPORT DOES NOT CONSTITUTE AN ADMISSION BY ANYONE THAT THE PRODUCT DESCRIBED IN THIS REPORT HAS ANY ¿DEFECTS¿ OR HAS ¿MALFUNCTIONED¿. THESE WORDS ARE INCLUDED IN THE FDA 3500A FORM AND ARE FIXED ITEMS FOR SELECTION CREATED BY THE FDA TO CATEGORIZE THE TYPE OF EVENT SOLELY FOR THE PURPOSE OF REGULATORY REPORTING. MEDTRONIC OBJECTS TO THE USE OF THESE WORDS AND OTHERS LIKE THEM BECAUSE OF THE LACK OF DEFINITION AND THE CONNOTATIONS IMPLIED BY THESE TERMS. THIS STATEMENT SHOULD BE INCLUDED WITH ANY INFORMATION OR REPORT DISCLOSED TO THE PUBLIC UNDER THE FREEDOM OF INFORMATION ACT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. A GOOD FAITH EFFORT WILL BE MADE TO OBTAIN THE APPLICABLE INFORMATION RELEVANT TO THE REPORT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

    Description of Event or Problem · 0

    MEDTRONIC RECEIVED INFORMATION VIA LITERATURE REGARDING CLINICAL OUTCOMES OF RE-DO TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) BASED UPON VALVE TYPES. ALL DATA WERE COLLECTED FROM AN INTERNATIONAL CLINICAL REGISTRY INVOLVING MULTIPLE CENTERS BETWEEN JANUARY 2008 AND APRIL 2021. THE STUDY POPULATION INCLUDED 312 PATIENTS WHO WERE PREDOMINANTLY MALE WITH A MEAN AGE OF 79 YEARS. THE PATIENTS HAD PREVIOUSLY UNDERGONE TAVR, BUT ENCOUNTERED STRUCTURAL DETERIORATION LEADING TO BIOPROSTHETIC AORTIC STENOSIS/REGURGITATION. THE PATIENTS THEN UNDERWENT RE-DO TAVR WHERE MULTIPLE MANUFACTURER¿S DEVICES WERE IMPLANTED, STRATIFIED BY BALLOON-EXPANDABLE VERSUS SELF-EXPANDING TAVR VALVES (BTAV VS STAV); 138 PATIENTS WERE IMPLANTED WITH A SELF-EXPANDING BIOPROSTHETIC VALVE (STAV), WHICH INCLUDED PATIENTS IMPLANTED WITH THE MEDTRONIC COREVALVE BIOPROSTHETIC VALVE. NO UNIQUE DEVICE IDENTIFIER NUMBERS WERE PROVIDED. AMONG ALL PATIENTS, FOUR DEATHS OCCURRED WITHIN 30 DAYS OF RE-DO TAVR AND 1-YEAR MORTALITY WAS 14.3% FOR BTAV AND 13.2% FOR STAV PATIENTS. NO FURTHER DETAILS WERE PROVIDED ON THE DEATHS AND THERE WAS NO STATEMENT OF CAUSAL OR CONTRIBUTORY RELATIONSHIP BETWEEN MEDTRONIC PRODUCT AND THE DEATHS. BASED ON THE AVAILABLE INFORMATION MEDTRONIC PRODUCT WAS NOT ASSOCIATED WITH THE DEATHS. AMONG ALL STAV PATIENTS, ADVERSE EVENTS INCLUDED: STROKE, VALVE MALPOSITIONING/MIGRATION, MAJOR VASCULAR/BLEEDING COMPLICATIONS, RESIDUAL MODERATE-SEVERE AORTIC REGURGITATION (AR) AND NEED FOR PERMANENT PACEMAKER IMPLANTATION (PPMI). BASED ON THE AVAILABLE INFORMATION MEDTRONIC PRODUCT MAY HAVE BEEN ASSOCIATED WITH THE ADVERSE EVENTS. NO ADDITIONAL ADVERSE PATIENT EFFECTS OR PRODUCT PERFORMANCE ISSUES WERE REPORTED.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1584840 COREVALVE TRANSCATHETER AORTIC VALVE AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV NPT MEDTRONIC HEART VALVES DIVISION CRS

    Patients

    Seq Age Sex Outcome Treatment
    1 79 YR Male Required Intervention| L